Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.26
GLAXF's Cash to Debt is ranked lower than
83% of the 763 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. GLAXF: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
GLAXF' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.48 Max: N/A
Current: 0.26
Equity to Asset 0.05
GLAXF's Equity to Asset is ranked lower than
97% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. GLAXF: 0.05 )
Ranked among companies with meaningful Equity to Asset only.
GLAXF' s Equity to Asset Range Over the Past 10 Years
Min: 0.05  Med: 0.24 Max: 0.4
Current: 0.05
0.05
0.4
Interest Coverage 2.58
GLAXF's Interest Coverage is ranked lower than
85% of the 461 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.94 vs. GLAXF: 2.58 )
Ranked among companies with meaningful Interest Coverage only.
GLAXF' s Interest Coverage Range Over the Past 10 Years
Min: 0.81  Med: 9.42 Max: 24.87
Current: 2.58
0.81
24.87
F-Score: 4
Z-Score: 1.34
M-Score: -2.56
WACC vs ROIC
8.63%
7.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 7.46
GLAXF's Operating margin (%) is ranked lower than
54% of the 708 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.77 vs. GLAXF: 7.46 )
Ranked among companies with meaningful Operating margin (%) only.
GLAXF' s Operating margin (%) Range Over the Past 10 Years
Min: 1.68  Med: 28.24 Max: 34.91
Current: 7.46
1.68
34.91
Net-margin (%) 2.51
GLAXF's Net-margin (%) is ranked lower than
65% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.28 vs. GLAXF: 2.51 )
Ranked among companies with meaningful Net-margin (%) only.
GLAXF' s Net-margin (%) Range Over the Past 10 Years
Min: 5.76  Med: 19.43 Max: 23.2
Current: 2.51
5.76
23.2
ROE (%) 11.14
GLAXF's ROE (%) is ranked higher than
64% of the 741 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.97 vs. GLAXF: 11.14 )
Ranked among companies with meaningful ROE (%) only.
GLAXF' s ROE (%) Range Over the Past 10 Years
Min: 17.3  Med: 61.93 Max: 84.89
Current: 11.14
17.3
84.89
ROA (%) 1.13
GLAXF's ROA (%) is ranked lower than
64% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. GLAXF: 1.13 )
Ranked among companies with meaningful ROA (%) only.
GLAXF' s ROA (%) Range Over the Past 10 Years
Min: 3.84  Med: 13.20 Max: 20.43
Current: 1.13
3.84
20.43
ROC (Joel Greenblatt) (%) 19.38
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 757 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.44 vs. GLAXF: 19.38 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GLAXF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 40.79  Med: 85.34 Max: 107.42
Current: 19.38
40.79
107.42
Revenue Growth (3Y)(%) -4.20
GLAXF's Revenue Growth (3Y)(%) is ranked lower than
74% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. GLAXF: -4.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GLAXF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.2  Med: 4.80 Max: 15.3
Current: -4.2
-4.2
15.3
EBITDA Growth (3Y)(%) -18.40
GLAXF's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 545 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. GLAXF: -18.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GLAXF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -18.4  Med: 6.60 Max: 17.4
Current: -18.4
-18.4
17.4
EPS Growth (3Y)(%) -17.90
GLAXF's EPS Growth (3Y)(%) is ranked higher than
75% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.20 vs. GLAXF: -17.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GLAXF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.2  Med: 4.85 Max: 51.3
Current: -17.9
-30.2
51.3
» GLAXF's 10-Y Financials

Financials (Next Earnings Date: 2016-07-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 110.34
GLAXF's P/E(ttm) is ranked lower than
91% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. GLAXF: 110.34 )
Ranked among companies with meaningful P/E(ttm) only.
GLAXF' s P/E(ttm) Range Over the Past 10 Years
Min: 6.35  Med: 14.70 Max: 119.52
Current: 110.34
6.35
119.52
Forward P/E 16.10
GLAXF's Forward P/E is ranked lower than
58% of the 69 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.86 vs. GLAXF: 16.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 110.34
GLAXF's PE(NRI) is ranked lower than
90% of the 539 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. GLAXF: 110.34 )
Ranked among companies with meaningful PE(NRI) only.
GLAXF' s PE(NRI) Range Over the Past 10 Years
Min: 6.38  Med: 14.71 Max: 115.85
Current: 110.34
6.38
115.85
Price/Owner Earnings (ttm) 31.52
GLAXF's Price/Owner Earnings (ttm) is ranked higher than
52% of the 259 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.02 vs. GLAXF: 31.52 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GLAXF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.83  Med: 16.46 Max: 45.91
Current: 31.52
4.83
45.91
P/B 24.86
GLAXF's P/B is ranked lower than
98% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.82 vs. GLAXF: 24.86 )
Ranked among companies with meaningful P/B only.
GLAXF' s P/B Range Over the Past 10 Years
Min: 5.48  Med: 9.07 Max: 26.1
Current: 24.86
5.48
26.1
P/S 2.85
GLAXF's P/S is ranked lower than
53% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. GLAXF: 2.85 )
Ranked among companies with meaningful P/S only.
GLAXF' s P/S Range Over the Past 10 Years
Min: 1.94  Med: 2.81 Max: 4.22
Current: 2.85
1.94
4.22
PFCF 129.23
GLAXF's PFCF is ranked lower than
89% of the 192 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.79 vs. GLAXF: 129.23 )
Ranked among companies with meaningful PFCF only.
GLAXF' s PFCF Range Over the Past 10 Years
Min: 8.24  Med: 16.93 Max: 135.68
Current: 129.23
8.24
135.68
POCF 25.89
GLAXF's POCF is ranked lower than
66% of the 251 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.79 vs. GLAXF: 25.89 )
Ranked among companies with meaningful POCF only.
GLAXF' s POCF Range Over the Past 10 Years
Min: 6.61  Med: 12.43 Max: 27.31
Current: 25.89
6.61
27.31
EV-to-EBIT 45.65
GLAXF's EV-to-EBIT is ranked lower than
83% of the 525 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.51 vs. GLAXF: 45.65 )
Ranked among companies with meaningful EV-to-EBIT only.
GLAXF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.60 Max: 48
Current: 45.65
6.3
48
EV-to-EBITDA 23.27
GLAXF's EV-to-EBITDA is ranked lower than
66% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.66 vs. GLAXF: 23.27 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLAXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.10 Max: 24.5
Current: 23.27
5.6
24.5
Shiller P/E 14.42
GLAXF's Shiller P/E is ranked higher than
90% of the 145 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.10 vs. GLAXF: 14.42 )
Ranked among companies with meaningful Shiller P/E only.
GLAXF' s Shiller P/E Range Over the Past 10 Years
Min: 11.71  Med: 15.14 Max: 22.32
Current: 14.42
11.71
22.32
Current Ratio 1.14
GLAXF's Current Ratio is ranked lower than
84% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. GLAXF: 1.14 )
Ranked among companies with meaningful Current Ratio only.
GLAXF' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.28 Max: 1.78
Current: 1.14
0.97
1.78
Quick Ratio 0.77
GLAXF's Quick Ratio is ranked lower than
85% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. GLAXF: 0.77 )
Ranked among companies with meaningful Quick Ratio only.
GLAXF' s Quick Ratio Range Over the Past 10 Years
Min: 0.68  Med: 0.99 Max: 1.42
Current: 0.77
0.68
1.42
Days Inventory 197.91
GLAXF's Days Inventory is ranked lower than
81% of the 659 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. GLAXF: 197.91 )
Ranked among companies with meaningful Days Inventory only.
GLAXF' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 190.92 Max: 202.64
Current: 197.91
167.28
202.64
Days Sales Outstanding 89.44
GLAXF's Days Sales Outstanding is ranked lower than
59% of the 610 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.16 vs. GLAXF: 89.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLAXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 74.32 Max: 93.9
Current: 89.44
54.62
93.9
Days Payable 128.20
GLAXF's Days Payable is ranked higher than
77% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.22 vs. GLAXF: 128.20 )
Ranked among companies with meaningful Days Payable only.
GLAXF' s Days Payable Range Over the Past 10 Years
Min: 62.75  Med: 333.04 Max: 372.4
Current: 128.2
62.75
372.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.61
GLAXF's Dividend Yield is ranked higher than
95% of the 565 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. GLAXF: 5.61 )
Ranked among companies with meaningful Dividend Yield only.
GLAXF' s Dividend Yield Range Over the Past 10 Years
Min: 2.72  Med: 5.06 Max: 6.24
Current: 5.61
2.72
6.24
Dividend Payout 6.37
GLAXF's Dividend Payout is ranked higher than
99% of the 371 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. GLAXF: 6.37 )
Ranked among companies with meaningful Dividend Payout only.
GLAXF' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.69 Max: 6.33
Current: 6.37
0.14
6.33
Dividend Growth (3y) 1.90
GLAXF's Dividend Growth (3y) is ranked lower than
65% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. GLAXF: 1.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
GLAXF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -12.6  Med: 7.00 Max: 20.8
Current: 1.9
-12.6
20.8
Forward Dividend Yield 5.21
GLAXF's Forward Dividend Yield is ranked higher than
96% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. GLAXF: 5.21 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 7.76
GLAXF's Yield on cost (5-Year) is ranked higher than
93% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.98 vs. GLAXF: 7.76 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
GLAXF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 3.76  Med: 7.00 Max: 8.63
Current: 7.76
3.76
8.63
3-Year Average Share Buyback Ratio 1.60
GLAXF's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 466 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -3.30 vs. GLAXF: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLAXF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20  Med: 1.10 Max: 3.6
Current: 1.6
-20
3.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.00
GLAXF's Price/Projected FCF is ranked higher than
58% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. GLAXF: 2.00 )
Ranked among companies with meaningful Price/Projected FCF only.
GLAXF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.61 Max: 21.79
Current: 2
0.97
21.79
Price/Median PS Value 1.02
GLAXF's Price/Median PS Value is ranked higher than
60% of the 637 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.16 vs. GLAXF: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
GLAXF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.17 Max: 3.33
Current: 1.02
0.71
3.33
Earnings Yield (Greenblatt) (%) 2.14
GLAXF's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 740 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. GLAXF: 2.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GLAXF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.1  Med: 9.50 Max: 15.8
Current: 2.14
2.1
15.8
Forward Rate of Return (Yacktman) (%) 8.56
GLAXF's Forward Rate of Return (Yacktman) (%) is ranked higher than
51% of the 316 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.27 vs. GLAXF: 8.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
GLAXF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4  Med: 12.80 Max: 40.6
Current: 8.56
4
40.6

More Statistics

Revenue(Mil) $35551
EPS $ 0.18
Beta1.20
Short Percentage of Float0.00%
52-Week Range $18.45 - 23.41
Shares Outstanding(Mil)4870.50

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 38,738 40,353 42,618
EPS($) 1.35 1.40 1.50
EPS without NRI($) 1.35 1.40 1.50

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NYSE:JNJ, NYSE:PFE, XSWX:NOVN, NYSE:MRK, NYSE:BMY, XPAR:SAN » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, GSK.Switzerland, GSK.UK, GSK.USA,
GlaxoSmithKline PLC was incorporated on 6 December 1999 in the United Kingdom. The Company creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. Its principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led healthcare company that researches and develops products in three pharmaceutical areas, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatrics and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. It has products in four main categories: Oral care, Nutritional, Total wellness, and Skin health. Its brands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for OTCPK:GLAXF

Headlines

Articles On GuruFocus.com
A Closer Look Into Veritas Pharma Apr 21 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Why the UK Is Headed For a Slowdown Mar 23 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Brandes Makes a Variety of Reductions in 4th Quarter Feb 11 2016 
10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
Stocks Bring High Dividend Yields to HOTCHKIS & WILEY Jan 14 2016 
Jeff Auxier's Holdings Trading Below Peter Lynch Earnings Line Jan 04 2016 
Cisco Systems, Microsoft and Intel Bring High Dividend Yields to First Eagle Investment Jan 04 2016 
High Dividend Yield Ratios Are Hallmarks of Many Dodge & Cox Stakes Dec 21 2015 

More From Other Websites
Glaxo's CEO Search Will Be `Relatively Expensive,' Chairman Says May 05 2016
GSK chairman rules out near-term break-up of drugmaker May 05 2016
GSK chairman rules out near-term break-up of drugmaker May 05 2016
GSK chairman rules out near-term break-up of drugmaker May 05 2016
How Did GlaxoSmithKline’s Consumer Healthcare Perform in 1Q16? May 05 2016
GlaxoSmithKline chairman says break-up not on the cards May 05 2016
GlaxoSmithKline chairman says break-up not on the cards May 05 2016
How Did GlaxoSmithKline’s Global Pharmaceuticals Business Perform? May 05 2016
GSK to sell, lease back, buildings in RTP May 04 2016
Is GlaxoSmithKline plc about to bomb? May 04 2016
Why GlaxoSmithKline plc, 3i Group plc and Barratt Developments plc should outperform the FTSE 100! May 04 2016
How Did GlaxoSmithKline’s Pharmaceutical Segment Perform in 1Q16? May 03 2016
How Is GlaxoSmithKline’s Growth Trending? May 03 2016
The numbers don’t lie, GlaxoSmithKline plc is set to beat AstraZeneca plc this year May 03 2016
GSK CEO: Big pharma should keep investing in R&D May 02 2016
France gets G7 to discuss global regulation of medicine prices May 02 2016
France gets G7 to discuss global regulation of medicine prices May 02 2016
GlaxoSmithKline’s Stock Rose on Solid 1Q16 Earnings Apr 30 2016
GSK reformulates mouthwash into a gel to prevent infections in newborns Apr 29 2016
Glaxo's Mouthwash-Inspired Gel for Babies Wins EU Agency Backing Apr 29 2016
Reformulated GSK mouthwash endorsed as umbilical cord antiseptic Apr 29 2016
GlaxoSmithKline (GSK) Q1 Earnings Lag, Revenues Up Y/Y Apr 28 2016
Have income investors forgotten just how good GlaxoSmithKline plc and Vodafone Group plc really are? Apr 28 2016
Glaxo Finally Finds Some Momentum Apr 27 2016
Britain's FTSE rises after Glaxo boost Apr 27 2016
GlaxoSmithKline Shares Boosted by Strong First-Quarter Update Apr 27 2016
[$$] GlaxoSmithKline Posts Healthy Profit With Earnings Rise Apr 27 2016
GSK finds axing doctor payments needn't torpedo sales Apr 27 2016
GSK finds axing doctor payments needn't torpedo sales Apr 27 2016
GSK finds axing doctor payments needn't torpedo sales Apr 27 2016
Britain's FTSE edges up after Glaxo boost Apr 27 2016
Strong sales growth and reduced costs boost GlaxoSmithKline plc’s results Apr 27 2016
GSK sees rise in sales of vaccines, healthcare products Apr 27 2016
GSK sees rise in sales of vaccines, healthcare products Apr 27 2016
GlaxoSmithKline rebound gathering pace, says outgoing CEO Apr 27 2016
GlaxoSmithKline rebound gathering pace, says outgoing CEO Apr 27 2016
Glaxo (GSK) Misses on Q1 Earnings, Revenues Rise Y/Y Apr 27 2016
Drugs giant GSK reports slump in profits Apr 27 2016
Better margins and new drugs keep GlaxoSmithKline on track Apr 27 2016
Drugs giant GSK reports slump in profits Apr 26 2016
GlaxoSmithKline first-quarter sales up 11% but profit falls Apr 26 2016
Pharma fight! Should you buy GlaxoSmithKline plc, Smith & Nephew plc or Hutchison China MediTech... Apr 26 2016
The Week ahead: GlaxoSmithKline plc, BP plc and Standard Chartered plc Apr 25 2016
Is It Time To Buy GlaxoSmithKline plc, Intertek Group plc & Weir Group plc? Apr 24 2016
What This Top Dividend Trust Is Holding Now: GlaxoSmithKline plc, BP plc And Royal Bank of Scotland... Apr 23 2016
GlaxoSmithKline promises reduced drug patents to help world's poor Mar 31 2016
GlaxoSmithKline promises reduced drug patents to help world's poor Mar 31 2016
GlaxoSmithKline promises reduced drug patents to help world's poor Mar 31 2016
GlaxoSmithKline's CEO Witty to bow out in March 2017 Mar 17 2016
GSK break-up? Don't bank on it, says drugmaker's outgoing boss Mar 17 2016
Longtime CEO of drug maker GSK to step down next year Mar 17 2016
Investor Woodford calls for outsider to head GlaxoSmithKline Mar 17 2016
GlaxoSmithKline CEO Witty to bow out in March 2017 Mar 17 2016
GlaxoSmithKline CEO Witty to bow out in March 2017 Mar 17 2016
Drugs giant GSK says boss to step down next year Mar 16 2016
Drugs giant GSK says CEO to step down next year Mar 16 2016
GSK asthma drug Nucala's long-term study supports safety profile Mar 05 2016
GlaxoSmithKline starts hunt for successor to CEO Witty Feb 29 2016
UK competition authorities fine GSK $54.5 million Feb 12 2016
UK watchdog fines GSK $54 million over 'pay-for-delay' drug deals Feb 12 2016
GSK dismisses near-term split as new drugs offset falling Advair Feb 03 2016
GSK dismisses near-term split as new drugs offset falling Advair Feb 03 2016
GSK dismisses near-term split as new drugs offset falling Advair Feb 03 2016
GSK refuses to be bounced into early consumer unit spin-off Feb 03 2016
GlaxoSmithKline posts loss of $616 million for 4th quarter Feb 03 2016
Drugs giant GSK says annual net profits triple Feb 02 2016
GSK and J&J back $1 billion biotech spin-off from Index Ventures Feb 02 2016
Five charged in U.S. with stealing secrets from GlaxoSmithKline Jan 21 2016
Five charged in US with trying to steal from pharma giant Jan 20 2016
Amgen reacquires rights to three drugs from Glaxo in 48 countries Dec 14 2015
Glaxo plans up to 20 new drug applications Nov 09 2015
GSK plan to file up to 20 new drugs by 2020 underwhelms market Nov 03 2015
GlaxoSmithKline net dips 26 percent in Q2 Oct 31 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK